@article{7fdafb585eb04a71997c27502a70af64,
title = "Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly",
abstract = "Background: Studies comparing primary medical treatment of acromegaly with surgery are often non-randomized, and not stratified by illness severity. We prospectively compared primary medical therapy with pituitary surgery in patients with acromegaly. All patients had macroadenomas, at least one random human growth hormone (GH) level ≥12.5 ng/mL, elevated IGF-I levels and failure to suppress GH to <1 ng/mL during an oral glucose tolerance test (oGTT). Methods: Forty-one patients from seven centers were randomized to primary treatment with octreotide LAR, 30 mg every 4 weeks × 3 months (ARM A, N = 15), or pituitary surgery (ARM B, N = 26) using a 1:2 randomization design. Patients cured by surgery (defined as nadir GH during oGTT <1 ng/mL and normal IGF-I) received no subsequent treatment. Those not cured surgically were then treated with octreotide LAR (SubArm B1) for 3 months. Results: Only one of the 15 patients in ARM A (6.7%) had normalization of both GH and IGF-I. In contrast, 13/26 patients had normalization of both GH and IGF-I after surgery alone (50%). Of the remaining 13 patients who did not normalize with surgery alone, treatment with octreotide LAR resulted in a normal nadir GH and normal serum IGF-I in 7 (53.9%). In total, 20/26 in ARM B (76.9%) experienced normalization of defined biochemical acromegaly parameters. Conclusions: Pituitary surgery alone was more effective than primary medical treatment (p = 0.006), and the combination of surgery followed by medical therapy was even more effective (p < 0.0001). Subjects treated with medical therapy after surgical debulking had a significant improvement in response rate compared to matched subjects treated with primary medical therapy.",
keywords = "Acromegaly, Octreotide, Surgery",
author = "Rudolf Fahlbusch and David Kleinberg and Beverly Biller and Vivien Bonert and Michael Buchfelder and Paolo Cappabianca and John Carmichael and William Chandler and Annamaria Colao and Ajax George and Anne Klibanski and Edmond Knopp and Juergen Kreutzer and Neehar Kundurti and Martin Lesser and Adam Mamelak and Rosario Pivonello and Kalmon Post and Brooke Swearingen and Vance, {Mary Lee} and Ariel Barkan",
note = "Funding Information: Acknowledgements The authors wish to acknowledge the invaluable contribution of Ms. Heather Levitt, who was instrumental in organizing the multicenter effort as well as the original development of the study materials. This study was supported by Novartis. Funding Information: The authors wish to acknowledge the invaluable contribution of Ms. Heather Levitt, who was instrumental in organizing the multicenter effort as well as the original development of the study materials. This study was supported by Novartis. This article is dedicated to the memory of Dr. David Kleinberg. The authors disclose the following potential conflict of interest issues: AB is a recipient of an Investigator Initiated Grant from Novartis and received consulting fees and honoraria from Novartis, Ipsen and Pfizer; BS owns stock from Novartis and Pfizer; AMC is a consultant and recipient of unrestricted research grants from Novartis and Ipsen; RP received consulting fees from Novartis, and honoraria and research funding from Ipsen and Pfizer; BB received research funding from Novartis and served as a consultant for Ipsen, Novartis and Pfizer; AK received grant support from Pfizer, is a consultant for Chiasma and is on a Scientific Advisory Board for Crinetics. The rest of the authors reported no potential conflict of interest. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media, LLC.",
year = "2017",
month = dec,
day = "1",
doi = "10.1007/s11102-017-0832-8",
language = "English",
volume = "20",
pages = "668--675",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "6",
}